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The Spontaneously Diabetic Torii (SDT) rat, a nonobese type 2 diabetes model, develops severe diabetic retinopathy as result
of chronic severe hyperglycemia. Although existing diabetes animal models also develop ocular complications, severe retinal
lesions frequently observed in human diabetes patients such as preretinal neovascularization or retinal detachment are not found.
Distinctive features in SDT rat are hypermature cataract, tractional retinal detachment with ﬁbrous proliferation, and massive
hemorrhaging in the anterior chamber. These pathophysiological changes are caused by sustained hyperglycemic condition and
subsequent increased expression of vascular endothelial growth factor (VEGF) in retina, iris, and ciliary body. Although some
diﬀerences in diabetic retinopathy exist between SDT rats and humans (e.g., a low incidence of neovascular formation and poor
development of nonperfused area are found in this animal), SDT rat will be a useful model in studies of the pathogenesis and
treatment of diabetic retinopathy.
1.Introduction
Many animal models have been used in research into dia-
betes mellitus (DM) and its complications. Animal models
of chemically induced DM such as streptozotocin (STZ)
or alloxan-induced diabetic animals are widely used [1].
Genetic models of DM such as Nonobese diabetic (NOD)
mice [2], Bio-Breeding (BB) rats [3], ob/ob mice [4], db/db
mice [5], Goto-Kakizaki (GK) rats [6], Zucker diabetic fatty
(ZDF) rats [7], and Otsuka Long-Evans Tokushima fatty
(OLETF) rats [8] are also used commonly. Although these
m o d e la n i m a l sd e v e l o pe i t h e rt y p e1( T 1 D )o rt y p e2( T 2 D )
diabetes and subsequent ocular complications, severe retinal
lesions frequently observed in human diabetes patients
such as preretinal neovascularization or retinal detachment
are not found; early pathological changes such as pericyte
loss [9, 10], early biophysiological changes such as retinal
leukostasis [11], and abnormal pattern in electroretinogram
(ERG) [12] are observed, at most.
The Spontaneously Diabetic Torii (SDT) rat, a nonobese
T2D model is an inbred rat strain established from Sprague-
Dawley (SD) rat by Shinohara et al. [13, 14]. As a result
of chronic severe hyperglycemia, SDT rats develop diabetic
retinopathy (DR) [13–20], diabetic peripheral neuropathy
[19, 20], and diabetic nephropathy [21]. Of these, severe DR
such as cataract, tractional retinal detachment with ﬁbrous
proliferation, and massive hemorrhaging in the anterior
chamber is a distinctive feature of SDT rat [13, 14]. Since the
establishment and the ﬁrst report of SDT rat by Shinohara
et al. [13], dozens of papers have been published. In the
present short paper, pathophysiological characteristics of
ocular complications in SDT rat are outlined.
2.GeneralCharacteristics
Male SDT rats exhibit noticeable hyperglycemia, polyuria,
and glucosuria concomitant with diminished blood insulin
levels and decreased body weight by 15–20 weeks of age
(Figure 1). The cumulative incidence of diabetes reaches
100% up to 40 weeks of age. In contrast, the incidence
is 33% in female SDT rats [13]. Preceding the onset of
diabetes, glucose intolerance with impaired insulin secretion
[13,22]andimpairedlipidcatabolism[23]arealsoobserved.
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Figure 1: Nonfasting plasma insulin and glucose levels in Spontaneously Diabetic Torii (SDT) rats and control Sprague-Dawley (SD) rats.
Diminish of pancreatic β-cells evokes hypoinsulinemia (a) and subsequent severe hyperglycemia (b) in SDT rats. Plasma glucose levels
sharply increase at 15–20 weeks of age and eventually reach a plateau, approximately 800mg/dL. Each value represents mean ± S.E.M. (N =
6–8).
quantitative trait loci (QTL) (Gisdt1, Gisdt2,a n dGisdt3)
for glucose intolerance on rat chromosomes 1, 2, and X,
respectively, indicating that the diabetic features in SDT
rat are polygenically inherited [24]. Hyperglycemia in SDT
rat is spontaneously developed, predominantly due to an
insulin secretory defect resulting from pathological damage
to the pancreatic islets, especially β-cells [22, 25]. Following
primary microvascular events in the pancreatic islet such
as congestion and hemorrhage (8–10 weeks), inﬂamma-
tion, progressive ﬁbrosis (10–20 weeks), and atrophy with
diminished β-cells (38 weeks) are observed [22]. These
inﬂammations are diﬀerent from autoimmune-mediated
inﬂammation observed in autoimmune diabetes. A major
locus on chromosome 3 (Dmsdt1)w a si d e n t i ﬁ e da sa
dominantlyacting SDTallelethatinducesisletinﬂammation
and ﬁbrosis [26].
3.OcularPathology
3.1. Lens. Cataract is the most frequently occurring ocular
complication in DM and is also often observed in dia-
betic animal models with certain disease duration (e.g.,
STZ-induced diabetic rats, ZDF rats). In male SDT rats,
macroscopic opacity of lens is observed by 40 weeks of
age (Figures 2(a) and 2(b))[ 13]. Lens clouding begins
at posterior pole of lens and ﬁnally progresses to mature
cataract. Histopathologically, hypermature cortical cataract
is suggested by severe swelling, vacuolation, liquefaction,
disintegration of the lens ﬁbers, and Morgani’s globules in
the lens cortex. Nuclear sclerosis and opaciﬁed lens cortex
are observed, and lens rupture is also found at this stage
[18]. Because of this mature cataract, fundus could not be
examined by ophthalmoscopy. Cataract in SDT rats was
completely prevented by glycemic control such as chronic
insulin treatment [17, 19, 20] and pancreatic transplantation
[27]. In addition, the histopathological changes of lens
were preceded by an increase in lens sorbitol content
(our unpublished data). These ﬁndings clearly indicate that
cataract in SDT rat is due to sustained hyperglycemia.
3.2. Vitreous Body. Proliferative diabetic retinopathy (PDR)
concerns new vessels extending into the vitreous cavity
and causing ﬁbrovascular proliferation, retinal detachment,
and vitreous hemorrhage. In SDT rats, the vitreous body
was shrunken and cortex was detached from the retina.
Proliferative ﬁbrovascular membrane was formed between
the folded retina and the distorted lens (Figures 2(c) and
2(d))[ 13, 16, 18]. Fibrovascular membrane was inﬁltrated
with inﬂammatory cells, and capillary vessels found in the
ﬁbrovascular membrane had thin walls. Vitreous hemor-
rhages were observed in some severe cases [18].
3.3. Retina. Among the many diabetic animal models, severe
retinal abnormality is a prominent feature of SDT rat. In
SDT rats, retina was locally thickened and formed retinal
folds and was detached from retinal pigmented epithelium.
These tractional changes of retina were observed only at the
center of retina, never at the peripheral retina (Figures 2(c)
and 2(d))[ 13, 15, 16, 18]. Immunostaining for albumin
showed marked leakage at the site of the tractional retinal
detachment, suggesting hyperpermeability of the retinal ves-
sels around the detachment site [16]. Fluorescein retinal ﬂat-
mount of SDT rats showed abnormal vascular formation,
includingvenousdilationandmeanderingvascularnetworks
(Figures 2(e) and 2(f))[ 16, 17]. Dilated retinal vessels and a
newly formed capillary network were also evident patholog-
ically. Slight hemosiderin deposition was found in the retinal
ganglion cell layer [16, 18]. Acellular capillaries and pericyteJournal of Ophthalmology 3
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Figure 2: Typical ocular observations in control male SD rats (a, c, e, and g) and SDT rats (b, d, f, and h). (a) and (b) macroscopic
photographs of eyes. Hypermature cataract is observed 100% in male SDT rats by 40 weeks of age. (c) and (d) histopathological changes in
lens and retina at 80 weeks old. Proliferative ﬁbrovascular membrane in vitreous is found around the optic disk. Retina is locally thickened
and formed a fold. Disintegration of lens is also observed. H&E stain. (e) and (f) ﬂuorescein angiomicroscopy at 80 weeks of age. Abnormal
vascular formation, including venous dilation and meandering vascular networks, is characteristically observed in SDT rats. Extensive
ﬂuorescein leakage is found around the optic disk. (g) and (h) anti-VEGF staining of iris at 80 weeks of age. VEGF immunoreactivity is
increased in iris of SDT rats. This may cause a massive hemorrhage on iris in some severe cases.
losswereobservedintrypsindigestionpreparation;however,
capillarymicroaneurysmswerenotevident[16,17].Vascular
nonperfusion area, bleeding, or hard/soft exudates were not
observed in ﬂat-mount preparations of retina from SDT rats
even at over 80 weeks of age [15].
3.4. Iris. Although the neovascular glaucoma is frequently
observed in human DR, iris neovascularization has not been
reported among diabetic animal models. Iris neovascular-
ization was found in some cases in SDT rats. Fibrovascular
tissue covering the pupil or anterior lens capsule may4 Journal of Ophthalmology
induce pupillary block or angle-closure glaucoma. In a
severe case, massive hemorrhage was found in the anterior
chamber [13, 16, 18]. Increased aqueous humor vascular
endothelial growth factor (VEGF) level [17], which may be
derived from anti-VEGF antibody positive ciliary epithelium
[28] and iris (Figures 2(g) and 2(h)), presumably causes
iris neovascularization and subsequent bleeding from the
neovasculature into the anterior chamber.
4.Electroretinogram(ERG)
ERG is used to detect abnormal function of the retina.
Prolongation of the peak latency in ERG is a very early
alteration in diabetic patients, even in patients having no
ophthalmoscopically visible alterations at this stage [29, 30].
STZ-induceddiabeticratsshowprolongationofpeaklatency
in ERG, and the prolongation is prevented with insulin
treatment [31, 32]. SDT rats also showed retinal dysfunction
in ERG earlier than histopathological changes [17, 33].
Both amplitudes and implicit times of the ERG in SDT
rats were not signiﬁcantly diﬀerent from those of SD rats
at prediabetic stage. However, at postdiabetic 44 weeks of
age, amplitudes of the a− and b−waves and the oscillatory
potentials (OPs) were reduced with prolonged implicit times
in SDT rats. Because OPs are preferentially decreased in
h u m a nD R ,t h i si sad i ﬀering characteristic between DR of
humans and SDT rats. The prolonged implicit times and
decreased amplitudes of OPs were clearly prevented with
long-termtreatmentof insulin [17],PKCβ-speciﬁcinhibitor,
JTT-010 [20], or an angiotensin II receptor blocker (ARB),
candesartan [34]. Therefore, depressed ERG in SDT rat is
caused by chronic hyperglycemia and may reﬂect vascular
and neuronal damage of retina, as frequently observed in
human DR.
5.VascularEndothelialGrowth
Factor (VEGF) and Pigment
Epithelium-DerivedFactor (PEDF)
VEGF plays an important role in retinal neovasculariza-
tion and hyperpermeability [35, 36]. Clinical observations
indicate that VEGF concentration in ocular ﬂuid positively
correlates with neovascularization activity in DR [37, 38].
In patients with DR and macular edema, increase of
vitreous and/or aqueous humor VEGF concentration has
been reported [38, 39]. Increased VEGF mRNA expression
and anti-VEGF staining area (e.g., retinal vessels, ganglion
cell layer, inner plexiform layer, outer plexiform layer, and
retinal pigment epithelium cells) in the retina of SDT rat are
reported [15, 40]. Increased aqueous humor VEGF level in
SDT rats tended to reduce by glycemic control with insulin
treatment [17]. Candesartan decreased the expression of
VEGF mRNA by reducing the accumulation of advanced
glycation end products (AGEs) [34] and NADPH oxidase
[41] in SDT rats. Gene transfer of the soluble form of VEGF
receptor Flt-1 (sﬂt-1), the endogenous speciﬁc inhibitor
of VEGF, into retina with adeno-associated viral (rAAV5)
vectors prevented the progress of DR in SDT rats [42].
Therefore, the increased expression of VEGF induced by
sustained hyperglycemia is thought to be causally related to
DR include retinal neovascularization in SDT rat.
On the other hand, expression of pigment epithelium-
derived factor (PEDF), a potent inhibitor of ocular angio-
genesis [43], is also upregulated in plasma of SDT rat
[44], and anti-PEDF antibody positive cells are detected in
retinal vessels, nerve ﬁber layer, ganglion cell layer, inner
plexiform layer, inner nuclear cell layer, outer plexiform
layer, and retinal pigment epithelium cells in SDT rats
[40]. These ﬁndings that VEGF and PEDF expressions were
both up-regulated in SDT rat retinae are diﬀerent from
the human DR with low levels of PEDF [45], and the
high PEDF levels in retina may have contributed to a low
incidence of neovascular formation and poor development
o fn o n p e r f u s e da r e ai nD Ro fS D Tr a t .
6. Conclusion
Human DR is characterized by microaneurysms, intraretinal
punctate hemorrhages, and macular edema. At advanced
stage, nonperfusion area and subsequent neovasculariza-
tion of the retina, which may extend into the vitreous
cavity, proliferation of ﬁbrous tissue, vitreous hemorrhage,
and retinal detachment, are frequently found. To study
and develop treatment for DR, animal models with DR
resembling human DR are desperately needed. The earliest
histopathological signs of DR such as selective loss of intra-
mural pericytes from retinal capillaries, capillary dilation,
and varicose loop formation are frequently observed in
some diabetic animal models (e.g., STZ-induced diabetic
rats) [46]. Meanwhile, SDT rats develop severe ocular
complications such as neovascularization and tractional
changes in retina. These ﬁndings are the main diﬀerences
betweenSDTratandotherrodentdiabetesmodels (Table 1).
The tractional changes caused by vitreoretinal interaction
are similar to those that occur in human PDR. There
is no rodent model with DR of such severity; therefore,
SDT rat may be the best candidate for research into DR.
One of the possible reasons why retinal neovascularization
is observed characteristically in SDT rat is the survival
period without glycemic control. In our laboratory, SDT rats
survived more than 90 weeks without insulin therapy. Under
chronic hyperglycemic circumstances, retina is exposed to
high concentration of VEGF over a long period. These
factors may cause thickening of the posterior vitreous cortex
or modiﬁed vitreo-retinal interaction [47] in SDT rats.
Meanwhile, in contrast to patients with DR, SDT rats did
not develop vascular nonperfusion, bleeding, or hard/soft
exudates in retina [15]. These may be crucial diﬀerences
between humans and rodents. Upregulation of PEDF may be
a possible cause of low incidence of neovascular formation
a n dn o n p e r f u s i o na r e ai nS D Tr a t[ 40].
In addition to retinal pathology, there are some other
similarities and diﬀerences in ocular pathology between
diabetic patients and SDT rats (Table 1). Senile cataract is
acceleratedindiabetics;however,truediabeticcataractisrare
condition, occurring typically in young people with acute
diabetes. On the other hand, SDT rats and other diabeticJournal of Ophthalmology 5
Table 1: Ocular pathological ﬁndings in diabetic human, SDT rats, and STZ-induced diabetic rats.
Human SDT rats STZ rats
Retina
Hyperpermeability Yes Yes Yes
Retinal detachment Yes Yes No
Retinal thickness Yes Yes Yes
Avascular area Yes No No
Neovascularization Yes Yes Yes
Retinal microaneurysm Yes No No
Pericyte loss Yes Yes Yes
Vessel abnormality Yes Yes Yes
VEGF expression High High High
PEDF expression Low High High
Vitreous body
Proliferative membrane Yes Yes No
Iris
Neovascularization Yes Yes No
Lens
Cataract Yes Yes Yes
(senile cataract   true diabetic cataract) (true diabetic cataract) (true diabetic cataract)
animals such as STZ-induced diabetic rats show typical
true diabetic cataract. The diﬀerence may be caused by
rapid progression of extreme hyperglycemia in these diabetic
animal models.
When the aqueous humor does not drain properly by
neovasculatures, increased intraocular pressure results in
glaucoma. Iris neovascularization and subsequent develop-
ment of neovascular glaucoma are serious consequences for
patients with PDR. Although diabetes may act as a risk factor
of open-angle glaucoma [48], there are no diabetic animal
models of spontaneously progress iris neovascularization.
However hyperpermeability in iris vessels and decreased
iris blood perfusion caused by iris vascular endothelial
dysfunctionarereported[49,50],irisneovascularizationwas
not found in STZ-induced diabetic rats. Since SDT rat shows
irisneovascularizationandbleeding fromtheneovasculature
in some severe cases, SDT rat is a useful model of diabetic
rubeosis and is expected as a model of diabetic glaucoma
[13, 14].
Although DR in SDT rat diﬀers from human DR in some
respects, these ocular lesions are much more severe than
those observed in other diabetic models and were clearly
prevented by glycemic control [17, 19, 20, 27]. To accelerate
the development of diabetes and its complications in SDT
rats, Masuyama et al. established SDT.Cg-Leprfa congenic
rats (SDT fatty rats) by introducing an fa allele of the leptin
receptor gene of Zucker Fatty rat into the genome of SDT
rats[51].Onsetofdiabetes inSDTfattyratisacceleratedto5
weeks of age by developing adiposity and insulin resistance.
Diabetic complications also develop at younger age than in
SDT rat [52].
In conclusion, severe ocular complications are distinctive
features of SDT rat and were “diabetic”, although there are
some diﬀerences from human DR. In view of the present
situation, that there are no ideal animal models of human
DR, SDT rat will be useful animal model in studies of the
pathogenesis of DR.
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